Fimasartan, anti-hypertension drug, suppressed inducible nitric oxide synthase expressions via nuclear factor-kappa b and activator protein-1 inactivation

Biological and Pharmaceutical Bulletin

Volumn 36, Issue 3, 2013, Pages 467-474

  Ryu, Suran ^a   Shin, Ji Sun ^a,b   Cho, Young Wuk ^a,b   Kim, Hyoung Kook ^c   Paik, Soo Heui ^c   Lee, Joo Han ^c   Chi, Yong Ha ^c   Kim, Ji Han ^c   Kim, Je Hak ^c   Lee, Kyung Tae ^a  

^a Kyung Hee University   (South Korea)

^b Kyung Hee University Hospital   (South Korea)

^c Boryung Pharm Co Ltd   (South Korea)

Author keywords

Activator protein 1; Fimasartan; Inflammation; Nitric oxide; Nuclear factor kappa B

Indexed keywords

ANTIHYPERTENSIVE AGENT; DNA; FIMASARTAN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; LIPOPOLYSACCHARIDE; NITRIC OXIDE; TRANSCRIPTION FACTOR AP 1;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL NUCLEUS; CONTROLLED STUDY; DNA BINDING; DOWN REGULATION; DRUG STRUCTURE; MACROPHAGE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TRANSCRIPTION REGULATION;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BIPHENYL COMPOUNDS; CELLS, CULTURED; LIPOPOLYSACCHARIDES; MACROPHAGES; MICE; NF-KAPPA B; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; PYRIMIDINES; TETRAZOLES; TRANSCRIPTION FACTOR AP-1;

EID: 84875495558     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b12-00859     Document Type: Article

References (42)

1. de Jong HJ, Vandebriel RJ, Saldi SR, van Dijk L, van Loveren H, Cohen Tervaert JW, Klungel OH. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and the risk of developing rheumatoid arthritis in antihypertensive drug users. Pharmacoepidemiol. Drug Saf., 21, 835-843 (2012).
2. Savoia C, Schiffrin E L. Inflammation in hypertension. Curr. Opin. Nephrol. Hypertens., 15, 152-158 (2006).
3. Sanchez-Lemus E , Murakami Y, Larrayoz-Roldan IM, Moughamian AJ, Pavel J, Nishioku T, Saavedra JM. Angiotensin II AT1 receptor blockade decreases lipopolysaccharide-induced inflammation in the rat adrenal gland. Endocrinology, 149, 5177-5188 (2008).
4. Savoia C, Schiffrin E L. Vascular inflammation in hypertension and diabetes: Molecular mechanisms and therapeutic interventions. Clin. Sci., 112, 375-384 (2007).
5. Zhou J, Ando H, Macova M, Dou J, Saavedra JM. Angiotensin II AT1 receptor blockade abolishes brain microvascular inflammation and heat shock protein responses in hypertensive rats. J. Cereb. Blood Flow Metab., 25, 878-886 (2005).
6. Bregonzio C, Armando I, Ando H, Jezova M, Baiardi G, Saavedra JM. Anti-inflammatory effects of angiotensin II AT1 receptor antagonism prevent stress-induced gastric injury. Am. J. Physiol. Gastrointest. Liver Physiol., 285, G414-G423 (2003).
7. Pang T, Benicky J, Wang J, Orecna M, Sanchez-Lemus E , Saavedra JM. Telmisartan ameliorates lipopolysaccharide-induced innate immune response through peroxisome proliferator-activated receptor-? activation in human monocytes. J. Hypertens., 30, 87-96 (2012).
8. Dandona P, Kumar V, Aljada A, Ghanim H, Syed T, Hofmayer D, Mohanty P, Tripathy D, Garg R. Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-?B, in mononuclear cells of normal subjects: Evidence of an antiinflammatory action. J. Clin. Endocrinol. Metab., 88, 4496-4501 (2003).
9. Dasu MR, Riosvelasco AC, Jialal I. Candesartan inhibits Toll-like receptor expression and activity both in vitro and in vivo. Atherosclerosis, 202, 76-83 (2009).
10. An J, Nakajima T, Kuba K, Kimura A. Losartan inhibits LPS-induced inflammatory signaling through a PPAR?-dependent mechanism in human THP-1 macrophages. Hypertens. Res., 33, 831-835 (2010).
11. Iwashita M, Sakoda H, Kushiyama A, Fujishiro M, Ohno H, Nakatsu Y, Fukushima T, Kumamoto S, Tsuchiya Y, Kikuchi T, Kurihara H, Akazawa H, Komuro I, Kamata H, Nishimura F, Asano T. Valsartan, independently of AT1 receptor or PPAR?, suppresses LPS-induced macrophage activation and improves insulin resistance in cocultured adipocytes. Am. J. Physiol. Endocrinol. Metab., 302, E286-E296 (2012).
12. Yanagitani Y, Rakugi H, Okamura A, Moriguchi K, Takiuchi S, Ohishi M, Suzuki K, Higaki J, Ogihara T. Angiotensin II type 1 receptor-mediated peroxide production in human macrophages. Hypertension, 33, 335-339 (1999).
13. Ma LJ, Corsa BA, Zhou J, Yang H, Li H, Tang YW, Babaev VR, Major AS, Linton MF, Fazio S, Hunley TE, Kon V, Fogo AB. Angiotensin type 1 receptor modulates macrophage polarization and renal injury in obesity. Am. J. Physiol. Renal Physiol., 300, F1203-F1213 (2011).
14. Lu H, Rateri DL, Feldman DL, Jr RJ, Fukamizu A, Ishida J, Oesterling E G, Cassis LA, Daugherty A. Renin inhibition reduces hypercholesterolemia-induced atherosclerosis in mice. J. Clin. Invest., 118, 984-993 (2008).
15. Kim JH, Park YM, Shin JS, Park SJ, Choi JH, Jung HJ, Park HJ, Lee KT. Fraxinellone inhibits lipopolysaccharide-induced inducible nitric oxide synthase and cyclooxygenase-2 expression by negatively regulating nuclear factor-kappa B in RAW264.7 macrophages cells. Biol. Pharm. Bull., 32, 1062-1068 (2009).
16. Michel T, Feron O. Nitric oxide synthases: Which, where, how, and why? J. Clin. Invest., 100, 2146-2152 (1997).
17. Ignarro LJ. Nitric oxide as a unique signaling molecule in the vascular system: A historical overview. J. Physiol. Pharmacol., 53, 503-514 (2002).
18. Kim TW, Yoo BW, Lee JK, Kim JH, Lee KT, Chi YH, Lee JY. Synthesis and antihypertensive activity of pyrimidin-4(3H)-one derivatives as losartan analogue for new angiotensin II receptor type 1 (AT1) antagonists. Bioorg. Med. Chem. Lett., 22, 1649-1654 (2012).
19. Shin BS, Kim TH, Paik SH, Chi YH, Lee JH, Tan HK, Choi Y, Kim M, Yoo SD. Simultaneous determination of fimasartan, a novel antihypertensive agent, and its active metabolite in rat plasma by liquid chromatography-tandem mass spectrometry. Biomed. Chromatogr., 25, 1208-1214 (2011).
20. Kim JY, Park SJ, Yun KJ, Cho YW, Park HJ, Lee KT. Isoliquiritigenin isolated from the roots of Glycyrrhiza uralensis inhibits LPSinduced iNOS and COX-2 expression via the attenuation of NF-?B in RAW264.7 macrophages. Eur. J. Pharmacol., 584, 175-184 (2008).
21. Lowenstein CJ, Alley E W, Raval P, Snowman AM, Snyder SH, Russell SW, Murphy WJ. Macrophage nitric oxide synthase gene: Two upstream regions mediate induction by interferon gamma and lipopolysaccharide. Proc. Natl. Acad. Sci. U.S.A., 90, 9730-9734(1993).
22. Lappas M, Permezel M, Georgiou HM, Rice GE. Nuclear factor ? B regulation of proinflammatory cytokines in human gestational tissues in vitro. Biol. Reprod., 67, 668-673 (2002).
23. Cai TG, Cai Y. Triterpenes from the fungus Poria cocos and their inhibitory activity on nitric oxide production in mouse macrophages via blockade of activating protein-1 pathway. Chem. Biodivers., 8, 2135-2143 (2011).
24. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: The control of NF-?B activity. Annu. Rev. Immunol., 18, 621-663 (2000).
25. Pauletto P, Rattazzi M. Inflammation and hypertension: The search for a link. Nephrol. Dial. Transplant., 21, 850-853 (2006).
26. Harrison DG, Guzik TJ, Lob HE, Madhur MS, Marvar PJ, Thabet SR, Vinh A, Weyand CM. Inflammation, immunity, and hypertension. Hypertension, 57, 132-140 (2011).
27. Pueyo ME, Gonzalez W, Nicoletti A, Savoie F, Arnal JF, Michel JB. Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-?B activation induced by intracellular oxidative stress. Arterioscler. Thromb. Vasc. Biol., 20, 645-651 (2000).
28. Zhang H, Sun GY. LPS induces permeability injury in lung microvascular endothelium via AT(1) receptor. Arch. Biochem. Biophys., 441, 75-83 (2005).
29. Ando H, Zhou J, Macova M, Imboden H, Saavedra JM. Angiotensin II AT1 receptor blockade reverses pathological hypertrophy and inflammation in brain microvessels of spontaneously hypertensive rats. Stroke, 35, 1726-1731 (2004).
30. Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, Tsutsui T, Ohnishi M, Sawaki M, Fujii M, Matsumoto T, Kinoshita M. Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor a, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure. J. Am. Coll. Cardiol., 35, 714-721 (2000).
31. MacMicking J, Xie QW, Nathan C. Nitric oxide and macrophage function. Annu. Rev. Immunol., 15, 323-350 (1997).
32. Lee SE, Kim YJ, Lee HY, Yang HM, Park CG, Kim JJ, Kim SK, Rhee MY, Oh BH, Investigators. E fficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): A 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension. Clin. Ther., 34, 552-568, e1-e9 (2012).
33. Shin JS, Yun CH, Cho YW, Baek NI, Choi MS, Jeong TS, Chung HG, Lee KT. Indole-containing fractions of Brassica rapa inhibit inducible nitric oxide synthase and pro-inflammatory cytokine expression by inactivating nuclear factor-?B. J. Med. Food, 14, 1527-1537 (2011).
34. Kobayashi Y. The regulatory role of nitric oxide in proinflammatory cytokine expression during the induction and resolution of inflammation. J. Leukoc. Biol., 88, 1157-1162 (2010).
35. Liu H, Liu X, Wei X, Chen L, Xiang Y, Yi F, Zhang X. Losartan, an angiotensin II type 1 receptor blocker, ameliorates cerebral ischemia-reperfusion injury via PI3K/Akt-mediated eNOS phosphorylation. Brain Res. Bull., 89, 65-70 (2012).
36. Sánchez-Lemus E , Benicky J, Pavel J, Saavedra JM. In vivo angiotensin II AT1 receptor blockade selectively inhibits LPS-induced innate immune response and ACTH release in rat pituitary gland. Brain Behav. Immun., 23, 945-957 (2009).
37. Ratajczak-Wrona W, Jablonska E , Garley M, Jablonski J, Radziwon P, Iwaniuk A. Role of AP-1 family proteins in regulation of inducible nitric oxide synthase (iNOS) in human neutrophils. J. Immunotoxicol., 1-8 (2012). DOI: 10.3109/1547691X.2012.686929.
38. Chi YH, Lee H, Paik SH, Lee JH, Yoo BW, Kim JH, Tan HK, Kim SL. Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects. Am. J. Cardiovasc. Drugs, 11, 335-346 (2011).
39. Meng Q, Xia Y. c-Jun, at the crossroad of the signaling network. Protein and Cell, 2, 889-898 (2011).
40. Zenz R, E ferl R, Scheinecker C, Redlich K, Smolen J, Schonthaler HB, Kenner L, Tschachler E , Wagner E F. Activator protein 1 (Fos/Jun) functions in inflammatory bone and skin disease. Arthritis Res. Ther., 10, 201-210 (2008).
41. Jurenka JS. Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: A review of preclinical and clinical research. Altern. Med. Rev., 14, 141-153 (2009).
42. Li Q, Verma IM. NF-kappaB regulation in the immune system. Nat. Rev. Immunol., 2, 725-734 (2002).